CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Product sales	$ 450,353	$ 921,675	$ 1,500,625	$ 1,836,157
License fee and other revenues	14,886	257,442	79,956	282,556
Research and development	16,987	144,322	189,419	330,702
Total revenues	482,226	1,323,439	1,770,000	2,449,415
Costs and Expenses:
Costs of goods sold	46,801	135,585	613,591	437,452
Research and development	28,843,102	12,491,290	71,680,166	39,765,180
Sales and marketing	2,365,975	302,509	3,781,959	703,440
General and administrative	6,853,767	10,514,243	14,346,449	13,969,783
Total costs and expenses	38,109,645	23,443,627	90,422,165	54,875,855
Operating loss	(37,627,419)	(22,120,188)	(88,652,165)	(52,426,440)
Changes in fair market value of warrant liabilities	9,835,441	(28,336,865)	(49,774,638)	(35,567,205)
Warrant related expenses		(7,649,395)		(7,649,395)
Interest expense	(10,900,381)	(1,369,955)	(13,821,273)	(4,109,866)
Interest and other income, net	1,129,489	64,574	1,927,811	219,536
Other financing expenses			(13,005,329)	(346,568)
Insurance reimbursement	1,930,233		6,296,370
Foreign currency transaction gain, net	74,514	91,471	181,659	(117,476)
Loss before income tax benefit	(35,558,123)	(59,320,358)	(156,847,565)	(99,997,414)
Net loss	(35,558,123)	(59,320,358)	(156,847,565)	(99,997,414)
Less: Net loss attributable to noncontrolling interest	(11,895)	(14,340)	(39,088)	(46,164)
Net loss attributable to Immunomedics, Inc. stockholders	$ (35,546,228)	$ (59,306,018)	$ (156,808,477)	$ (99,951,250)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):	$ (0.21)	$ (0.55)	$ (1.08)	$ (0.97)
Weighted average shares used to calculate loss per common share (basic and diluted)	166,054,266	107,839,947	145,119,409	102,756,818
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	$ (66,419)	$ (52,247)	$ (155,058)	$ 58,569
Unrealized gain (loss) on securities available for sale	10,321	5,467	585	(52,489)
Other comprehensive (loss) income, net of tax:	(56,098)	(46,780)	(154,473)	6,080
Comprehensive loss	(35,614,221)	(59,367,138)	(157,002,038)	(99,991,334)
Less comprehensive loss attributable to noncontrolling interest	(11,895)	(14,340)	(39,088)	(46,164)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	$ (35,602,326)	$ (59,352,798)	$ (156,962,950)	$ (99,945,170)